Joining forces: A call for greater collaboration to study new medicines in children and adolescents with type 2 diabetes

25Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A collaborative effort will facilitate the collection of adequate and well-controlled pediatric efficacy and safety clinical trial data to inform pediatric use of new drugs to treat T2D. An approach relying on a multiarm trial is one particularly attractive approach that leverages efficiencies gained from use of a shared control group, with efficiencies gained from a shared research infrastructure. Success in pediatric drug development has often involved collaboration. Indeed, reliance on consortia-based approaches to evaluate novel therapies was successful for other relatively uncommon pediatric diseases (e.g., juvenile idiopathic arthritis and schizophrenia) and should be met with similar success in T2D.

Cite

CITATION STYLE

APA

Karres, J., Pratt, V., Guettier, J. M., Temeck, J., Tamborlane, W. V., Dunger, D., … Tomasi, P. (2014, October 1). Joining forces: A call for greater collaboration to study new medicines in children and adolescents with type 2 diabetes. Diabetes Care. American Diabetes Association Inc. https://doi.org/10.2337/dc14-0494

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free